Diastolic blood pressure J-curve phenomenon in a tertiary-care hypertension clinic by Lip, Stefanie et al.
767
Hypertension is the single largest modifiable risk factor for cardiovascular events,1 with treatment guidelines in-
formed by unequivocal evidence for benefit with pharmaco-
logical blood pressure (BP) lowering in randomized controlled 
trials.2 However, one of the unresolved controversies in hyper-
tension management over the last 40 years is the issue of the di-
astolic J curve3,4—reduction in diastolic blood pressure (DBP) 
<85 to 90 mm Hg was not associated with lower risks, and re-
duction <70 to 80 mm Hg resulted in increased coronary events 
but not stroke.5,6 Most of the evidence for the J curve comes 
from observational studies or post hoc analyses of randomized 
controlled trials.7–9 The studies providing evidence for the J 
curve were also plagued by reverse causality and regression 
dilution bias.10,11 Moreover, the natural decrease in DBP with 
age after 55 years of age causes a late-life bias and a nonlinear 
distortion between mortality risk and risk factor in mixed-age 
adult follow-up cohorts.12,13
In the Framingham and the CALIBER (Cardiovascular 
Disease Research Using Linked Bespoke Studies and 
Electronic Health Records) studies, the diastolic J curve 
was observed only in the presence of high systolic blood 
pressure (SBP; ie, high pulse pressure).14–16 However, in the 
CLARIFY registry (Prospective Observational Longitudinal 
Registry of Patients with Stable Coronary Artery Disease) reg-
istry, the diastolic J curve persisted in patients with coronary 
heart disease, even among those in the lowest pulse pressure 
range.17 Additionally, a recent post hoc analysis of high-
risk patients from the ONTARGET (Ongoing Telmisartan 
Alone and in Combination with Ramipril Global Endpoint) 
and TRANSCEND (Telmisartan Randomised Assessment 
Study in Angiotensin Converting Enzyme Inhibitor Intolerant 
Subjects with Cardiovascular Disease) trials showed that both 
achieved SBP <120 mm Hg and DBP <70 mm Hg were as-
sociated with increased cardiovascular and all-cause deaths,18 
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even when the achieved SBP was within optimal range of 120 
to 140 mm Hg.19
The clinical importance of the role of diastolic J curve, if 
present, continues to be a matter of debate primarily because 
of the conflicting reports noted above and focus on intensive 
BP lowering in recent guidelines.20,21 The 2018 European 
Society of Cardiology/European Society of Hypertension 
guidelines recommend a DBP target of <80 mm Hg in only 
those without established coronary heart disease.21 Currently, 
<50% of patients treated for hypertension achieve a target 
office SBP <140 mm Hg; however, with the new guidelines 
emphasizing a greater focus on lower target BP, more clarity is 
required on the risks of the diastolic J curve, if present.
The key objective of the present study was to study the 
associations of on-treatment office DBP measured during a 
5-year period on cause-specific cardiovascular hospital admis-
sions and mortality during a 30-year follow-up period in a 
real-life hypertensive cohort.
Materials and Methods
Data will be available on request to third parties through the Glasgow 
Safe Haven (details available at https://www.nhsggc.org.uk/about-us/
professional-support-sites/nhsggc-safe-haven/).
Study Setting and Study Population
The Glasgow Blood Pressure Clinic (GBPC) located in the Greater 
Glasgow area is the largest and the main specialist hypertension clinic 
in Glasgow, which provides secondary- and tertiary-level service to 
patients with hypertension. Further details on the study population 
and measurements have been described previously.22 In brief, patients 
were referred to the GBPC if their BPs were not controlled in pri-
mary care with at least 3 drugs or if there was evidence of high-risk 
factors such as early-onset hypertension and a family history of pre-
mature CVD. Structured instruments were used to collect data from 
all patients attending the clinic and were stored electronically in a 
single computerized database, which contains information on 16 011 
patients attending the clinic from 1969 to 2011. The West of Scotland 
Research Ethics Service of the National Health Service (NHS) has 
approved analysis of anonymized data from the GBPC database (11/
WS/0083). The ethics committee approves analysis of anonymized 
clinical data of patients collected during routine clinical care for pa-
tient care and for patient benefit. The data are held securely in an 
NHS-approved secure site, and anonymized extracts are permitted for 
analyses. All patients attending the NHS are informed that their data 
will be used for analyses for patient benefit, to improve clinical prac-
tice and patient safety.
BP Measurements
The GBPC used specialist hypertension nurses who are experienced 
and highly trained in BP measurement and follow contemporary 
guidelines (https://bihsoc.org/resources/bp-measurement/measure-
blood-pressure/). The procedure required subjects to rest for 5 min-
utes in a seated position before BP was manually measured using 
standard sphygmomanometers. BP devices validated by the British 
and Irish Hypertension Society were used for BP measurements at 
the clinic. Clinical practice was refreshed with publication of new 
guidelines from the British and Irish Hypertension Society during the 
duration of the study. Three BP measurements were performed, 1 mi-
nute apart, and the mean of the second and third measurements was 
recorded. Patients attending the clinic were advised to take their reg-
ular medications as usual. Each patient attended the same clinic and 
would have their BP measured in the same 3-hour window either in 
the morning or evening on each visit. Drug substitution, addition, and 
dose adjustment occurred during follow-up and was in accordance 
with clinical guidelines. Prescribed medications were cross-checked 
with patients at each clinic visit, and adherence with treatment was 
strongly advised. However, dietary intake and the level of physical 
exertion before each clinic appointment could not be controlled. A 
more accurate measure of the time between drug consumption and 
BP measurements was unavailable. Information on specific medica-
tions, their doses, and formal concordance testing was unavailable.
In addition to baseline BP, we calculated average BP over 2 lon-
gitudinal time periods: year 1 and years 2 to 5. To be included in each 
time frame, subjects were required to have a minimum of 3 BP read-
ings ≥30 days apart. We calculated the mean BP for each time frame 
using a time-weighted average of all BP measurements during the 
interval to remove any upward bias of the mean BP caused by more 
frequent appointments when BP was uncontrolled. Patients >25 years 
of age were included in the outcome analyses, which were performed 
in the overall group and in 2 age categories (age <60 and ≥60 years) 
recognizing the natural decline in DBP and a consequent increase in 
pulse pressure after the age of 55 years.
Outcome and Comorbidity Assessment
Hospital admissions and mortality data were available from 1980 
to March 2013 and were obtained from the NHS Information and 
Statistics Division. In Scotland, the NHS provides primary and sec-
ondary health care to all citizens, free at point of access. The diag-
noses from the patients’ admissions were available from Information 
and Statistics Division according to the World Health Organization 
Classification of Diseases (International Classification of Diseases–
Ninth Revision before 1996 and International Classification of 
Diseases–Tenth Revision after 1996). Comorbidities at baseline, 
1-year, and 5-year follow-up were determined using the Charlson co-
morbidity score.23 The morbidity outcomes were the first admission 
with any cardiovascular event, myocardial infarction (MI), ischemic 
heart disease (IHD), cerebrovascular accident (CVA), heart failure 
(HF), and peripheral vascular disease. The mortality outcomes were 
all-cause deaths, cardiovascular deaths, IHD deaths, CVA deaths, 
and noncardiovascular deaths. The patients were followed from first 
BP clinic visit until death, emigration, or the end of follow-up on 
April 1, 2011.
Statistical Analysis
Baseline and longitudinal characteristics were summarized overall 
and by age groups (age <60 and ≥60 years). Continuous variables 
were presented as mean±SD and categorical data as numbers and per-
centages. Comparisons between the age categories were made using 
either independent t tests for continuous variables or χ2 test for cate-
gorical variables.
The relationship between cause-specific morbidity and mortality 
events and 5-year longitudinal BP was assessed by a time-dependent, 
Cox proportional hazard (PH) model, in which baseline, 1-year aver-
age BP, and 2- to 5-year average BP measurements were included in 
the model as the major time-dependent predictor variables (ie, taking 
account of varying BP between subsequent visits) in univariate anal-
ysis. Data were censored when patients had a primary outcome event, 
died, or left Scotland. A Multivariable Cox PH model was adjusted 
for baseline variables, age, sex, body mass index, cholesterol, smok-
ing status, and Charlson comorbidity index as time-dependent vari-
able. A variable on year of the first visit strata (epochs) was used to 
adjust the secular trend in mortality and was divided into 5 categories 
(first visit, 1977 or before, between years 1978 and 1985, 1986 and 
1993, 1994 and 2001, 2002, and thereafter). Time-dependent analy-
ses were performed using time intervals at 1 and 5 years of follow-up. 
In addition, time-dependent postbaseline DBP was divided into 4 
groups, <80, 80 to 89.9 (referrant), 90 to 99.9, and ≥100 mm Hg, and 
analyzed accordingly in the Cox PH model. All the above analyses 
were performed separately for the 2 age group categories. The multi-
variable adjusted relationship between BP and cause-specific events 
was also assessed using a time-dependent, Cox PH model with re-
stricted cubic splines, which allows for nonlinearity without assum-
ing any specific contour. A P value of <0.05 (2 sided) was considered 
statistically significant for all tests. Log-minus-log plots were ana-
lyzed for any suggestion of deviation from the PH assumption. We 
performed 2 multivariable adjusted Cox analysis: model 1 (included 
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SBP and DBP), adjusted for age, sex, body mass index, smoking, 
cholesterol, SBP, and DBP as time-dependent variables, epochs and 
Charlson score; model 2 (excluded SBP), adjusted for age, sex, body 
mass index, smoking, cholesterol, and DBP as time-dependent varia-
ble, epochs and Charlson score. We also constructed cubic splines for 
SBP and DBP from model 1 and DBP from model 2.
Competing risk regression based on the Fine-Gray proportional 
subhazards model was performed, and subdistribution hazard ratio 
(HR) and 95% CI were calculated to estimate the risk of DBP <80 
mm Hg according to cardiovascular or noncardiovascular outcomes. 
The cumulative incidence function was used to graph the rates of 
outcomes, thus accounting for the competing risk. All analyses were 
performed using R, version 3.5.1 (https://www.R-project.org/).
Results
Baseline Demographics
There were 10 355 eligible patients categorized into 2 age 
groups (age <60 and ≥60 years). Table 1 shows the baseline 
demographics and longitudinal BP characteristics of the study 
population. The average age was 52 years with nearly equal 
proportion of men and women overall. Around 15% of the 
overall cohort had DBP <80 mm Hg, and 29% had DBP ≥100 
mm Hg. Patients with age ≥60 years had a greater proportion 
of women, higher SBP, lower DBP, and higher Charlson co-
morbidity score. Table 2 summarizes the patient characteristics 
by DBP categories and shows the DBP <80 mm Hg group is 
older with a greater proportion of women, lower proportion of 
smokers, and lower comorbidity scores.
Outcome Analyses
In the entire cohort of 10 355 patients, there were 2956 primary 
outcome events (cardiovascular admissions+cardiovascular 
deaths) over 110 979 person-years of follow-up, 2960 all-
cause deaths over 131 064 person-years, and 1299 cardiovas-
cular deaths over 145 548 person-years. In the age <60 years 
subgroup, there were 1769 primary outcomes over 85 182 
person-years, whereas age ≥60 years subgroup had 1187 pri-
mary outcomes over 25 796 person-years of follow-up. Table 
S1 in the online-only Data Supplement summarizes all-cause–
specific events and person-years of follow-up.
We performed 2 multivariable adjusted Cox analyses: one 
with adjustment for SBP as time-dependent variable (model 
1) and the second excluding SBP (model 2), along with 
other covariates. We constructed cubic splines for SBP and 
DBP from model 1 and DBP from model 2, and the plots are 
presented in Figure 1. There was a clear linear relationship 
between higher SBP and greater risk of the primary cardiovas-
cular outcome, all nonfatal cardiovascular events except HF 
admissions, all-cause mortality, and cardiovascular mortality. 
In model 2 where the effect of SBP is not accounted for, there 
is a substantial increase in risk at higher levels of DBP for all 
outcomes except noncardiovascular and IHD mortality. When 
SBP is accounted for in the model, the effects are specific for 
DBP, and these results are described in more detail below and 
full results presented in Figures 1 and 2 and Table S2.
We describe the observed nonlinear relationships between 
DBP and outcomes using 3 terms—U shaped, if the relation-
ship is symmetrical across a nadir DBP level with increas-
ing risks at higher and lower levels of DBP from the nadir; 
J shaped, if the relationship is asymmetrical with clear aug-
mentation of risk with increasing DBP from the nadir; re-
verse J shaped, for an asymmetrical nonlinear relationship 
with clear augmentation of risk with decreasing DBP from 
the nadir. For the primary composite cardiovascular outcome 
(cardiovascular admissions+cardiovascular deaths), the rela-
tionship with DBP was U shaped with the nadir of risk at 92 
(model 1) or 86 mm Hg (model 2) and substantially and signif-
icantly increased HRs for the highest and lowest DBP groups 
(Figure 1). The HRs for the primary cardiovascular outcome 
after adjustment for SBP (model 1) were 1.38 (95% CI, 1.18–
1.62) and 1.24 (95% CI, 1.04–1.49) for DBP <80 and DBP 
≥100, respectively, compared with reference DBP 80 to 90 
group (Figure 1; Table S2). In contrast, subgroup age <60 and 
≥60 years showed, respectively, a strong reverse J-shaped and 
a weak U-shaped relationship for the primary outcome. For 
subgroup age <60 years, the HRs for DBP <80 and DBP ≥100 
were 1.57 (95% CI, 1.21–2.03) and 1.16 (95% CI, 0.91–1.49), 
respectively, whereas for age ≥60 years, they were 1.23 (95% 
CI, 1–1.5) and 1.27 (95% CI, 0.96–1.69), respectively.
For cardiovascular admissions, the relationship with DBP 
was U-shaped (nadir at DBP of 93 mm Hg) with model 1 
but J-shaped relationship with model 2 (nadir at DBP of 85 
mm Hg; Figure 1). The U-shaped relationship evident for car-
diovascular admissions reflects the net contribution different 
Table 1. Demographics and Blood Pressure Characteristics of the Study 
Population
Variable Overall <60 y ≥60 y
n 10 355 7108 3247
Age, y 52.30 (14.93) 44.54 (10.54) 69.29 (6.83)
Women (%) 5591 (54.0) 3594 (50.6) 1997 (61.5)
Ever smokers (%) 4279 (41.3) 2946 (41.4) 1333 (41.1)
Cholesterol, mmol/L 5.87 (1.16) 5.86 (1.13) 5.89 (1.21)
BMI 28.28 (5.78) 28.52 (6.04) 27.76 (5.13)
Baseline SBP, mm Hg 159.08 (26.22) 154.53 (24.14) 169.03 (27.79)
Baseline DBP, mm Hg 93.83 (13.23) 95.24 (12.77) 90.72 (13.70)
SBP (Avg), 1 y 152.69 (19.17) 148.69 (16.80) 160.14 (20.99)
DBP (Avg), 1 y 90.84 (9.29) 92.69 (8.50) 87.41 (9.73)
SBP (Avg), 2–5 y 145.93 (16.69) 142.97 (14.91) 151.70 (18.37)
DBP (Avg), 2–5 y 87.19 (8.46) 89.10 (7.54) 83.47 (8.91)
Charlson score, 1 y (%)
  0 4150 (40.1) 4150 (58.4) 0
  1 2681 (25.9) 2681 (37.7) 0
  2 2072 (20.0) 277 (3.9) 1795 (55.3)
  3 1117 (10.8) 0 1117 (34.4)
  4+ 335 (3.2) 0 335 (10.3)
DBP categories (%)
  <80 mm Hg 1570 (15.2) 838 (11.8) 732 (22.5)
  80–89.9 mm Hg 2645 (25.5) 1721 (24.2) 924 (28.5)
  90–99.9 mm Hg 3144 (30.4) 2276 (32.0) 868 (26.7)
  ≥100 mm Hg 2996 (28.9) 2273 (32.0) 723 (22.3)
Avg indicates average; BMI, body mass index; DBP, diastolic blood pressure; 
and SBP, systolic blood pressure.
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risk profiles of its constituents—reverse J shaped for MI, 
IHD, and HF admissions but J/U shaped for CVA admis-
sions (Figure 1; Table S2). Stratifying by age, both age <60 
and ≥60 years show J-shaped relationships with different pat-
terns of contributions from their constituent outcomes. For 
the age <60 subgroup, MI and HF admissions showed no re-
lationship with DBP while IHD admissions showed a clear 
reverse J-shaped relationship while CVA admissions showed 
a clear U-shaped relationship. For the age ≥60 subgroup, a 
clear reverse J-shaped relationship was seen for MI, IHD, and 
HF admissions while CVA admissions showed no association 
with DBP categories.
Mortality analyses showed a reverse J-shaped relationship 
for all-cause mortality with DBP, primarily because DBP< 80 
group associated with substantially and significantly increased 
risk of noncardiovascular mortality (1.56 [95% CI, 1.28–1.9]) 
and a slightly higher risk for IHD mortality (1.36 [95% CI, 
1.01–1.84]) compared with the referrant group (Figure 2; 
Table S2). The mortality results were primarily driven by 
age ≥60 subgroup, which showed strong reverse J-shaped 
relationship for all-cause mortality and noncardiovascular 
mortality with comparable HRs to the overall analysis. Age 
<60 subgroup showed a significantly increased risk only for 
all-cause mortality in the DBP ≥100 category (1.4 [95% CI, 
1.02–1.93]).
Competing Risk Analysis
Figure 3 shows the estimated cumulative incidence functions 
for DBP <80 and DBP ≥80 mm Hg based on model 1 for com-
posite cardiovascular outcomes and noncardiovascular mor-
tality indicating the increased risk associated with DBP <80 
mm Hg for both cardiovascular and noncardiovascular out-
comes. DBP <80 mm Hg was associated with increased risk 
of cardiovascular outcomes (subdistribution hazard, subdis-
tribution HR, 1.33; 95% CI, 1.169–1.51; P=1.46×10−5), and 
these estimates were comparable to the cause-specific hazards 
obtained from the traditional Cox PH analyses.
Discussion
The results of this observational study of 10 355 treated hyper-
tensive patients extends and adds to current understanding of 
the diastolic J curve in hypertension. As expected, we observed 
evidence for a linear relationship for SBP and a nonlinear re-
lationship for DBP with a range of cardiovascular outcomes. 
Our results show that while DBP <80 mm Hg is associated 
with increased risk for first admissions with IHD, MI, and 
HF, it does not translate to increased cardiovascular mortality. 
After stratifying by age, DBP <80 mm Hg is associated with 
increased risk of admissions with IHD and HF in both the 
older and younger age groups; however increased risk of CVA 
was evident only in the younger subgroup (<60 years). We 
observed an increased risk of noncardiovascular mortality with 
DBP <80 mm Hg, which was surprising. Competing risk anal-
ysis confirmed increased risk associated with DBP <80 mmHg 
for cardiovascular outcomes after accounting for the risk of 
noncardiovascular mortality. Our results suggest that the short-
term adverse cardiovascular impact of intensive DBP lowering 
does not translate into long-term mortality risk, and one pos-
sible reason may be the long-term beneficial effect of the con-
comitant low SBP that accompanies low DBP. The surprising 
result of increased noncardiovascular mortality with low DBP 
may indicate reverse causality, and this warrants further study.
Table 2. Demographics by DBP Categories at Baseline
Variable <80 mm Hg 80–89.9 mm Hg 90–99.9 mm Hg ≥100 mm Hg P Value
n 1570 2645 3144 2996  
Age, y 55.88 (18.02) 52.61 (15.67) 51.07 (14.43) 51.46 (12.47) <0.001
Female (%) 919 (58.5) 1544 (58.4) 1685 (53.6) 1443 (48.2) <0.001
Ever smokers (%) 608 (38.7) 1021 (38.6) 1276 (40.6) 1374 (45.9) <0.001
Cholesterol, mmol/L 5.69 (1.14) 5.78 (1.10) 5.87 (1.14) 6.06 (1.20) <0.001
BMI 27.70 (5.52) 28.20 (5.77) 28.31 (5.72) 28.63 (5.97) <0.001
Baseline SBP, mm Hg 141.09 (24.74) 149.50 (21.50) 157.72 (20.86) 178.38 (23.79) <0.001
Baseline DBP, mm Hg 73.54 (6.40) 86.10 (2.87) 95.39 (2.89) 109.63 (6.87) <0.001
SBP (Avg), 1 y 149.99 (20.50) 149.56 (19.09) 150.36 (18.07) 157.01 (19.01) <0.001
DBP (Avg), 1 y 80.04 (8.94) 85.87 (7.83) 90.78 (6.99) 96.13 (8.02) <0.001
SBP (Avg), 2–5 y 145.85 (17.50) 145.63 (16.56) 144.38 (16.22) 147.63 (16.81) <0.001
DBP (Avg), 2–5 y 79.85 (9.22) 84.55 (7.89) 87.81 (7.18) 90.71 (7.64) <0.001
Charlson score, 1 y (%)     <0.001
  0 527 (33.6) 1042 (39.4) 1348 (42.9) 1233 (41.2)
  1 270 (17.2) 609 (23.0) 856 (27.2) 946 (31.6)
  2 330 (21.0) 572 (21.6) 595 (18.9) 575 (19.2)
  3 322 (20.5) 318 (12.0) 273 (8.7) 204 (6.8)
  4+ 121 (7.7) 104 (3.9) 72 (2.3) 38 (1.3)
Avg indicates average; BMI, body mass index; DBP, diastolic blood pressure; and SBP, systolic blood pressure.
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The J-curve controversy stems from observations of a 
nonlinear relationship between DBP and cardiovascular risk.24 
Additionally, there is a specific diastolic J-curve relationship, 
which is evident in the presence of coronary artery disease and 
explained by limited coronary flow reserve.4 While there is 
consistent evidence from a majority of studies in hypertensive 
patients that lowering DBP (as defined by achieved BP or on-
treatment BP <70) is associated with increased risk of coronary 
events,14,16–19,25 this relationship was not evident in a study of 
1.2 million patients not selected for hypertension.15 For mor-
tality outcomes, the results of our study concur with SYS-EUR 
(Systolic Hpertension in Europe Trial),25 which also studied 
treated hypertensive patients, but not with the CLARIFY reg-
istry, which analyzed patients with CAD and hypertension.17 
The Framingham study of recurrent CVD in subjects with 
isolated systolic hypertension and prevalent CVD showed an 
association of recurrent CVD with DBP <70 irrespective of 
pulse pressure levels.16 The key criticism against the J-curve 
phenomenon is reverse causality, where the higher risk seen 
with low DBP may be due to severe underlying chronic condi-
tions including cancer or HF, which are associated with low 
BPs. The HOT study (Hypertension Optimal Treatment26; age, 
50–80 years) indicated that the J-curve relationship between 
DBP and coronary events could be explained by underlying 
pathology such as poor LV function, poor general health, and 
artery stiffness. A post hoc analysis of SPRINT (Systolic BP 
Intervention Trial),27 which included only hypertensive sub-
jects over the age of 50 years, showed a U-shaped relationship 
between baseline DBP and the primary composite outcome, 
but intensive SBP lowering showed reduced risk across all 
baseline quintiles of DBP. Our results concur with the results 
of SPRINT for composite cardiovascular outcomes among the 
age ≥60 years group. Additionally, our study demonstrates the 
higher risk for nonfatal cardiovascular events with low DBP is 
Figure 1. Cubic splines for the adjusted hazard ratios for time to 30-y cause-specific hospital admissions and cause-specific deaths. Shaded areas indicate 
95% CIs. Three results are presented for each outcome: the relationship between systolic blood pressure (SBP) on cause-specific outcomes using model 1 
where both SBP and diastolic blood pressure (DBP) are included in the model; the relationship between DBP and cause-specific outcomes using model 1 
where both SBP and DBP are included in the model; and the relationship between DBP and cause-specific outcomes using model 2 where SBP is excluded 
from the model. CV indicates cardiovascular; CVA, cerebrovascular accident; HF, heart failure; IHD, ischemic heart disease; LnHR, logarithm of hazard ratio; 
and MI, myocardial infarction.
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Figure 2. Forest plot of hazard ratios (HRs) with 95% CI for 30-y cause events by diastolic blood pressure categories (model 1). All HRs were calculated 
using diastolic blood pressure of 80 to 89.9 mm Hg as the referrant category. The left column presents the results from the overall cohort analysis while the 
middle and right columns show the results for the subgroups <60 y and >60 y, respectively. CV indicates cardiovascular; CVA, cerebrovascular accident; HF, 
heart failure; IHD, ischemic heart disease; and MI, myocardial infarction.
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prominent in the younger age group, which is not represented 
in the SPRINT study.
Additionally, higher pulse pressure reflecting increased ar-
terial stiffness may partially explain the J-curve phenomenon 
for DBP. While general population cohorts (Framingham14: 
age, 30–62 years; CALIBER15: age, 30–80 years) showed a 
J-shaped relationship only in those with high pulse pressure, 
a reanalysis of the INVEST trial (International Verapamil 
SR-Trandolapril)28 (age, 66±10 years), REACH registry 
(Reduction of Atherothrombosis for Continued Health)29 (age, 
68±10 years), and CLARIFY17 (age, 65±10 years) showed 
increased cardiovascular risk for both high and low pulse pres-
sure. Recent intensive BP-lowering trials such as ACCORD 
(Action to Control Cardiovascular Risk in Diabetes)8 and 
SPRINT7 did not show a J curve between BP and outcomes. A 
reanalysis of the TNT trial (Treating to New Targets) showed 
that in patients with coronary artery disease, a J- or U-shaped 
relationship with SBP and DBP was present.6 In this study, all 
patients who had coronary artery disease were 61 years of age 
and were not on antihypertensives. It is well known that DBP 
decreases after the age of 55 years with consequent increase 
in pulse pressure in older patients, and hence age may explain 
some of the variability in results. Because age is the strongest 
marker of pulse pressure, we tried to overcome this by analyz-
ing patients <60 and >60 years of age separately in our study. 
Our finding of the J curve in both older and younger subgroups 
for IHD admissions supports the adverse impact of intensive 
DBP lowering on cardiovascular risk but not mortality.
Comparable with previous studies, we did not observe a 
nonlinear relationship for CVA mortality in either age group 
and for cardiovascular admissions in age ≥60 group. However, 
age <60-year subgroup showed a clear U-shaped relationship 
between DBP and CVA admissions. This novel finding sug-
gests analyses without stratifying by age or studies of cohorts 
>60 years may attribute a neutral risk from DBP on CVA risk. 
CVA death showed a linear relationship with DBP in the age 
<60-year subgroup and neutral effects in the older subgroup.
The ARIC study (Atherosclerosis Risk in Communities)30 
showed those with DBP of 60 to 69 mm Hg had a higher 
prevalence of baseline high-sensitivity cardiac troponin >14 
ng/L compared with those with DBP of 80 to 89.9 mm Hg. 
This suggests that low DBP might be causing ongoing sub-
clinical myocardial damage. Our results in this context may 
reflect unmasking of ongoing myocardial damage by pharma-
cological lowering of DBP to <80 mm Hg by the increased 
incidence of IHD and HF admissions. However, further re-
search is required to establish the best screening method, and 
studies of high-sensitivity cardiac troponin I and NT-proBNP 
(N-terminal pro-B-type natriuretic peptide) as potential safety 
biomarkers for screening during intensive BP reduction are 
attractive options.31–33
Ours is an observational study, so we cannot fully address 
reverse causality. Nevertheless, to explore patterns in associa-
tion that would shed insight into the J-curve phenomenon, we 
conducted separate analyses for patients >60 and <60 years 
of age and additionally adjusted for comorbidities at baseline, 
Figure 3. Cumulative incidence functions for 
primary cardiovascular (CV) outcome and non-
CV mortality by diastolic blood pressure (DBP) 
categories.
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1 year, and 5 years of follow-up. We show cause- and age-
specific differences in the pattern of nonlinear association 
between DBP and cardiovascular outcomes. Low DBP is sig-
nificantly associated with MI and HF admissions only in the 
older subgroup and CVA in the younger subgroup. While we 
did not see a strong association between low DBP and car-
diovascular mortality, there was a borderline increased risk 
of IHD mortality with DBP <80. Importantly, CVA deaths 
showed a consistent linear trend for increased risk with 
increasing DBP. Our study highlights the complex nature of 
DBP on cardiovascular outcomes, which may partially ex-
plain variable results from previous studies and should in-
form future studies.
The main strengths of our study are the analysis of a large 
cohort of real-world treated hypertensive subjects with ≤30-
year follow-up, high event rates, and analysis of cause-spe-
cific morbidity and mortality outcomes. We also addressed 
reverse causality and the effect of pulse pressure by stratifying 
our analysis by age and analyzing cause-specific morbidity 
and mortality separately. The main limitations are single-
center secondary/tertiary-care cohort, observational nature of 
the study, lack of data on patient adherence, physician inertia, 
use of clinic BP and not out-of-office measurements. We used 
health record linkage across the NHS in Scotland to detect car-
diovascular admission and mortality events. While this would 
not pick up events occurring outside Scotland, data from ran-
domized clinical trials conducted in Scotland using record 
linkage, such as WOSCOPS (West of Scotland Coronary 
Prevention Study), show a low level of underreporting in re-
cord linkage data and suggest that this is not a major issue.34
 
Indeed, these data indicate that cardiovascular outcome de-
tection using record linkage in a clinical trial performed in a 
country with a unified health system, such as Scotland, would 
likely lead to qualitatively similar outcomes to those obtained 
by the current expensive clinical trial model involving rig-
orous individual patient follow-up and intensive data collec-
tion.35 Measurement of BP by the GBPC clinic nurses may 
have changed over the years because of changes in the British 
and Irish Hypertension Society measurement guidelines. We 
also have not adjusted for treatment differences either in terms 
of drug classes prescribed or treatment titration because of 
lack of prescription data. Baseline alcohol intake in our cohort 
did not show significant association with cardiovascular out-
comes and may likely reflect the effect of advice that patients 
receive at every clinic visit on lifestyle modification and lim-
iting alcohol intake. The generalizability of our findings needs 
to be confirmed through independent studies.
Perspectives
Increased cardiovascular morbidity attributable to lower-
ing DBP <80 mmHg in treated hypertensive patients does 
not translate to increased cardiovascular mortality. Evolving 
hypertension treatment guidelines recommend more inten-
sive BP reduction may lead to unintended consequences of 
higher healthcare utilization because of increased cardiovas-
cular morbidity, and this merits future prospective studies. 
For reasons unclear, low on-treatment DBP is associated with 
increased risk of noncardiovascular mortality, and this merits 
further study.
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What Is New?
•	 Low diastolic blood pressure (BP) is associated with increased risk of 
cardiovascular morbidity but not of cardiovascular mortality in both older 
and younger hypertensive patients.
What Is Relevant?
•	The diastolic J curve needs to be considered in the management of 
treated hypertensive patients. Intensive diastolic BP lowering may not be 
associated with long-term mortality risks.
Summary
There is still a need for another adequately powered randomized 
controlled trial of high-risk hypertensive patients randomized to 
target diastolic BP <90, <80, and <70 mm Hg to establish the non-
linear relationship between diastolic BP and outcomes. Evolving 
new hypertension guidelines promoting lower systolic BP targets 
will require prospective monitoring to assess the impact on mor-
bidity and cost-effectiveness. Whether additional cardiovascular 
monitoring is required to safely achieve lower BP targets warrants 
further study.
Novelty and Significance
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